Fundraising FoxNXT2B
Venture capitalUppsala · Seed–Growth · 4 people tracked
Find your way into NXT2B
Sign up to see every warm intro you have to NXT2B
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NXT2B team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
NXT2B is a fully privately owned venture capital firm that funds investments with its own capital, enabling fast decisions without reliance on external funding. It partners with competent, ambitious entrepreneurs and focuses on growth equity investments in healthcare, medical devices, and specialty pharmaceutical companies, while also backing technology and consumer companies with distinctive ideas. The firm targets early-phase projects of high scientific quality with reasonable commercial potential, committing to long-term relationships. NXT2B emphasizes active ownership, working alongside portfolio management teams to build market-leading companies, and draws on proven experience commercializing innovative projects.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's website & public directories
Erika has over 20 years in the life science sector, previously serving as CFO of OxThera, VP and CFO of Q-Med, and CFO and CEO of BioPhausia. She holds a B.Sc. in Business and Economics from Uppsala University and began her career as an auditor at Ernst & Young.
Angelica is CEO of Lokon Pharma AB and a Professor of Immunotherapy at Uppsala University, working in immune, gene and cell therapy with a focus on cancer and autoimmune disease.
Swedish entrepreneur who founded NXT2B in 2011 and now serves as senior adviser. He previously held senior positions at Pharmacia and Biomatrix and founded Q-Med (maker of Restylane), later sold to Galderma. He has also served on the board of the Swedish Foundation for Strategic Research and chaired Stockholm Uppsala Life Science.
Per-Olof has 50 years of experience in the pharmaceutical and biotech industry, holding senior roles at Merck AB, Astra AB, Pharmacia AB and Bristol-Myers Squibb AB. He has served as CEO of Karo Bio AB, Melacure Therapeutics AB and Q-Med AB.
Investments · 9 tracked
founders shown can be your intro pathOther
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AllgoHolding ABHansa Biopharma ABLokon Pharma ABLumina Adhesives ABNavinci Diagnostics ABQ-linea ABRepos Pharma ABScint-X ABVivolux AB
Frequently asked questions
- How many investments has NXT2B made?
- NXT2B has 9 tracked investments.
- What stage does NXT2B invest at?
- NXT2B invests at the Seed, Series A, Growth stages.
- What sectors does NXT2B focus on?
- NXT2B focuses on Biotech, Consumer, Healthtech, Medical Devices.
- Where is NXT2B located?
- NXT2B is headquartered in Uppsala, SE.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.